Literature DB >> 12218168

Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection.

Heiner Wedemeyer1, Xiao-Song He, Michelina Nascimbeni, Anthony R Davis, Harry B Greenberg, Jay H Hoofnagle, T Jake Liang, Harvey Alter, Barbara Rehermann.   

Abstract

The cellular immune response contributes to clearance of hepatitis C virus (HCV) and persists for decades after recovery from infection. The immunological basis for the inefficiency of the cellular immune response in chronically infected persons is not known. Here, we used four HLA-A2 tetramers, specific for two HCV core and two HCV NS3 epitopes, to investigate at the single-cell level effector function and phenotype of HCV-specific CD8+ T cells in 20 chronically infected and 12 long-term recovered patients. Overall, HCV-specific, tetramer+ T cells were more frequently found in PBMCs of chronically infected patients than in those of recovered patients. However, when compared with HCV-tetramer+ T cells of recovered patients, they displayed an impaired proliferative capacity. As a result of the impaired proliferative capacity, HCV-specific T cell lines derived from chronically infected patients displayed less peptide-specific cytotoxicity than those from recovered patients. In addition, proliferation and ex vivo IFN-gamma production of HCV-tetramer+ cells, but not influenza-virus-specific T cells, were defective in chronically infected patients and could not be restored by in vitro stimulation with peptide and IL-2. At least three distinct phenotypes of HCV-specific CD8+ T cells were identified and associated with certain functional characteristics. In addition, impairment of proliferative, cytokine, and cytotoxic effector functions of tetramer+ T cells in viremic patients was associated with weak ex vivo HCV-specific CD4+ T cell responses. Thus, the defective functions of HCV-specific CD8+ T cells might contribute to viral persistence in chronically infected patients, and knowledge on their reversibility may facilitate the development of immunotherapeutic vaccines.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12218168     DOI: 10.4049/jimmunol.169.6.3447

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  213 in total

Review 1.  Memory CD8 T-cell differentiation during viral infection.

Authors:  E John Wherry; Rafi Ahmed
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

2.  Viral replicative capacity is the primary determinant of lymphocytic choriomeningitis virus persistence and immunosuppression.

Authors:  Andreas Bergthaler; Lukas Flatz; Ahmed N Hegazy; Susan Johnson; Edit Horvath; Max Löhning; Daniel D Pinschewer
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-22       Impact factor: 11.205

3.  The clinical relevance of persistent recombinant immunoblot assay-indeterminate reactions: insights into the natural history of hepatitis C virus infection and implications for donor counseling.

Authors:  Addisalem T Makuria; Sukanya Raghuraman; Peter D Burbelo; Cathy C Cantilena; Robert D Allison; Joan Gibble; Barbara Rehermann; Harvey J Alter
Journal:  Transfusion       Date:  2012-02-05       Impact factor: 3.157

4.  Monocyte activation by interferon α is associated with failure to achieve a sustained virologic response after treatment for hepatitis C virus infection.

Authors:  Dennis J Hartigan-O'Connor; Din Lin; James C Ryan; Valentina A Shvachko; Myrna L Cozen; Mark R Segal; Norah A Terrault; Lewis L Lanier; M Michele Manos; Joseph M McCune
Journal:  J Infect Dis       Date:  2013-12-10       Impact factor: 5.226

5.  Level, phenotype and activation status of CD4+FoxP3+ regulatory T cells in patients chronically infected with human immunodeficiency virus and/or hepatitis C virus.

Authors:  N I Rallón; M López; V Soriano; J García-Samaniego; M Romero; P Labarga; P García-Gasco; J González-Lahoz; J M Benito
Journal:  Clin Exp Immunol       Date:  2009-01       Impact factor: 4.330

6.  The frequency of CD127(+) hepatitis C virus (HCV)-specific T cells but not the expression of exhaustion markers predicts the outcome of acute HCV infection.

Authors:  Eui-Cheol Shin; Su-Hyung Park; Michelina Nascimbeni; Marian Major; Laura Caggiari; Valli de Re; Stephen M Feinstone; Charles M Rice; Barbara Rehermann
Journal:  J Virol       Date:  2013-02-06       Impact factor: 5.103

7.  Ex vivo analysis of human memory CD4 T cells specific for hepatitis C virus using MHC class II tetramers.

Authors:  Cheryl L Day; Nilufer P Seth; Michaela Lucas; Heiner Appel; Laurent Gauthier; Georg M Lauer; Gregory K Robbins; Zbigniew M Szczepiorkowski; Deborah R Casson; Raymond T Chung; Shannon Bell; Gillian Harcourt; Bruce D Walker; Paul Klenerman; Kai W Wucherpfennig
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

8.  Relation between viral fitness and immune escape within the hepatitis C virus protease.

Authors:  J Söderholm; G Ahlén; A Kaul; L Frelin; M Alheim; C Barnfield; P Liljeström; O Weiland; D R Milich; R Bartenschlager; M Sällberg
Journal:  Gut       Date:  2005-08-16       Impact factor: 23.059

9.  Cellular immune responses associated with occult hepatitis C virus infection of the liver.

Authors:  Juan A Quiroga; Silvia Llorente; Inmaculada Castillo; Elena Rodríguez-Iñigo; Margarita Pardo; Vicente Carreño
Journal:  J Virol       Date:  2006-11       Impact factor: 5.103

10.  Evidence of viral adaptation to HLA class I-restricted immune pressure in chronic hepatitis C virus infection.

Authors:  Silvana Gaudieri; Andri Rauch; Lawrence P Park; Elizabeth Freitas; Susan Herrmann; Gary Jeffrey; Wendy Cheng; Katja Pfafferott; Kiloshni Naidoo; Russell Chapman; Manuel Battegay; Rainer Weber; Amalio Telenti; Hansjakob Furrer; Ian James; Michaela Lucas; Simon A Mallal
Journal:  J Virol       Date:  2006-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.